Wedbush Equities Analysts Cut Earnings Estimates for Geron

Key Points

• Wedbush analysts have revised their earnings estimate for Geron Corporation to $0.84 per share for FY2028, down from a previous forecast of $0.86.
• Despite posting quarterly revenue of $49.04 million, Geron's net margin remains negative at 53.52%, reflecting ongoing financial challenges.
• Several brokerages, including Scotiabank, have downgraded Geron's stock rating and significantly decreased their target prices, indicating a negative outlook from market analysts.

Geron Corporation (NASDAQ:GERN - Free Report) - Analysts at Wedbush reduced their FY2028 earnings per share estimates for Geron in a research report issued to clients and investors on Wednesday, August 6th. Wedbush analyst R. Driscoll now forecasts that the biopharmaceutical company will post earnings of $0.84 per share for the year, down from their prior estimate of $0.86. The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron's FY2029 earnings at $1.01 EPS.

A number of other brokerages have also recently issued reports on GERN. Scotiabank cut Geron from a "sector outperform" rating to a "sector perform" rating and dropped their target price for the stock from $4.00 to $1.50 in a report on Thursday, May 8th. The Goldman Sachs Group assumed coverage on Geron in a report on Thursday, July 10th. They issued a "sell" rating and a $1.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $4.19.

Geron Price Performance

Shares of GERN traded down $0.02 during mid-day trading on Monday, reaching $1.44. The company had a trading volume of 6,295,368 shares, compared to its average volume of 12,701,930. Geron has a twelve month low of $1.09 and a twelve month high of $4.83. The company has a debt-to-equity ratio of 0.46, a current ratio of 7.87 and a quick ratio of 6.79. The company's 50-day moving average is $1.38 and its 200-day moving average is $1.63. The company has a market capitalization of $915.56 million, a P/E ratio of -11.05 and a beta of 0.73.

Geron (NASDAQ:GERN - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%. The business had revenue of $49.04 million during the quarter, compared to analysts' expectations of $47.30 million. During the same period in the prior year, the firm posted ($0.10) EPS. Geron's quarterly revenue was up 5455.6% compared to the same quarter last year.

Institutional Investors Weigh In On Geron

Hedge funds and other institutional investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC acquired a new stake in Geron during the 4th quarter valued at $36,000. GF Fund Management CO. LTD. acquired a new stake in Geron during the 4th quarter valued at $45,000. 111 Capital acquired a new stake in Geron during the 4th quarter valued at $52,000. Fifth Lane Capital LP acquired a new stake in Geron during the 4th quarter valued at $53,000. Finally, Harvest Investment Services LLC acquired a new stake in Geron during the 4th quarter valued at $61,000. 73.71% of the stock is owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.